Please provide your email address to receive an email when new articles are posted on . Researchers used data from the GRIPHON study and open-label extension study. The median selexipag dose was 1,000 ...
Please provide your email address to receive an email when new articles are posted on . Selexipag improved pulmonary vascular resistance and other hemodynamic variables among patients with chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results